QUOTE AND NEWS
TheStreet.com  Apr 4  Comment 
NEW YORK (TheStreet) -- Halozyme plunged Friday morning after the biopharmaceutical company announced that it would temporarily suspend enrollment in an ongoing Phase 2 trial of its PEGPH20 treatment of patients with pancreatic cancer. The...
StreetInsider.com  Apr 4  Comment 
Halozyme Therapeutics, Inc. (Nasdaq: HALO) 29% LOWER; announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in an...
Wall Street Journal  Apr 4  Comment 
Halozyme said it is temporarily halting patient enrollment and dosing of its PEGPH20 treatment in an ongoing Phase 2 trial in patients with pancreatic cancer.
FierceBiotech  Apr 4  Comment 
Halozyme has pressed pause on a Phase II trial of its lead cancer candidate over safety concerns, news that sent the biotech's shares down 25% on Friday morning.
Benzinga  Apr 4  Comment 
Halozyme Therapeutics (NASDAQ: HALO) fell 23.73% to $8.84 in pre-market trading after the company announced the temporary halt of Phase 2 trial enrollment. Ocean Power Technologies (NASDAQ: OPTT) dipped 17.89% to $3.12 in the pre-market session...
StreetInsider.com  Mar 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Halozyme+%28HALO%29+CONSISTENT+1+Met+Primary+Endpoint/9330610.html for the full story.
newratings.com  Mar 28  Comment 
SOUTH SAN FRANCISCO (dpa-AFX) - Halozyme Therapeutics Inc (HALO) said Friday the European Commission has approved Roche's (RHHBY) new subcutaneous formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and...
newratings.com  Mar 26  Comment 
WASHINGTON (dpa-AFX) - The FDA has approved Actavis plc's (ACT) Metronidazole 1.3% Vaginal Gel, an antibiotic, for the treatment of bacterial vaginosis. Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals...
StreetInsider.com  Mar 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Halozyme+%28HALO%29+Met+Primary+Endpoint+in+HTI-501+Phase+12/9312956.html for the full story.
SeekingAlpha  Feb 27  Comment 
Halozyme Therapeutics (HALO) Q4 2013 Earnings Call February 27, 2014 4:30 pm ET Executives Schond Greenway Helen I. Torley - Chief Executive Officer, President and Director David A. Ramsay - Chief Financial Officer and Vice...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki